Atypical p-ANCA: What a Positive Test Result Means

A positive atypical p-ANCA result tells you that your immune system is making antibodies that target components of your own white blood cells, but in a pattern distinct from the one seen in classic small-vessel vasculitis. Rather than pointing to a single diagnosis, the finding is most closely tied to inflammatory bowel disease (particularly ulcerative colitis), autoimmune liver conditions like primary sclerosing cholangitis and autoimmune hepatitis, and occasionally lupus-spectrum disorders. The word “atypical” matters here because it signals that the antibodies recognize different molecular targets and behave differently under the microscope than the ANCA patterns doctors typically associate with kidney- and lung-damaging vasculitis. Understanding what this result does and does not mean can save you from unnecessary worry and help guide the next steps in your workup.

How Atypical p-ANCA Looks Different Under the Microscope

ANCA testing usually starts with a technique called indirect immunofluorescence, where a lab applies your blood serum to a slide of fixed white blood cells and looks for glowing patterns. Classic c-ANCA produces a fine, granular glow spread across the cell’s interior, while classic p-ANCA gives a neat, smooth rim of fluorescence hugging the area around the nucleus. Atypical p-ANCA looks noticeably different from both. Researchers have described two subtypes: one produces a broad, uneven glow around the nucleus, and the other combines that uneven perinuclear glow with coarser granular staining throughout the rest of the cell. A distinctive clue is the presence of multiple bright spots within the nucleus itself, something never seen with classic p-ANCA or c-ANCA.¹ Those intranuclear foci are one of the hallmarks that experienced lab technicians use to flag an ANCA result as atypical rather than classic.

In one study that categorized all ANCA-positive sera, roughly a third of the fluorescence patterns fell into the atypical category, distinct from both “classical” c-ANCA and the flat, homogeneous cytoplasmic pattern.² That proportion underscores how common this pattern is in clinical practice; it is far from a rare curiosity.

What the Antibodies Are Actually Reacting With

In classic vasculitis-associated ANCA, the main targets are two well-defined proteins inside neutrophils: myeloperoxidase (MPO) for p-ANCA and proteinase 3 (PR3) for c-ANCA. Atypical p-ANCA, by contrast, does not go after MPO. Research has identified a roughly 50-kilodalton protein sitting in the nuclear envelope of neutrophils and other myeloid cells as one major target. When antibodies purified against this protein were tested, they produced a nuclear rim-like glow on myeloid cells, consistent with the atypical perinuclear pattern.³

Other neutrophil proteins have been studied as potential targets in patients with ulcerative colitis. In one investigation of over 100 ulcerative colitis patients, the most common targets were lactoferrin (found in about a third of patients) and elastase (about a quarter), while MPO was not a target in any of the patients tested.⁴ Additional proteins like cathepsin G, bactericidal/permeability-increasing protein, and lysozyme have all been explored as serological markers in IBD and other diseases.⁵ The practical takeaway is that atypical p-ANCA is not one antibody hitting one target; it is a family of antibodies directed at several neutrophil components, which is part of why the fluorescence pattern varies.

Ulcerative Colitis and Crohn’s Disease

The strongest and best-studied disease association for atypical p-ANCA is ulcerative colitis. A systematic review of the link between p-ANCA and inflammatory bowel disease confirmed that p-ANCA is more strongly associated with ulcerative colitis than with Crohn’s disease.⁶ This makes the test clinically useful when a gastroenterologist is trying to distinguish between the two conditions, which can look similar on endoscopy.

In diagnostic accuracy terms, one study found that atypical p-ANCA had a sensitivity of 44% and a specificity of 86% for ulcerative colitis, with a positive predictive value of 78%.⁷ In plain language, a negative result does not rule ulcerative colitis out (many people with UC test negative), but a positive result, taken alongside other clinical findings, adds meaningful weight toward an ulcerative colitis diagnosis over Crohn’s. It is a piece of the diagnostic puzzle, not the whole picture.

In children, a similar pattern holds. Research on pediatric IBD patients found that serum p-ANCA and PR3-ANCA (but not MPO-ANCA) were effective at distinguishing ulcerative colitis from other forms of IBD, and that combining ANCA testing with other antibody markers like ASCA could also help gauge disease activity and phenotype.⁸

Autoimmune Liver Disease

Beyond the gut, atypical p-ANCA shows up frequently in two autoimmune liver conditions: primary sclerosing cholangitis (PSC) and autoimmune hepatitis (AIH). Both diseases share a strong overlap with IBD, and both are considered autoimmune disorders with atypical features partly because of the atypical ANCA pattern they produce.⁹ In autoimmune hepatitis, atypical p-ANCA has been reported in anywhere from about half to over 90% of patients with type 1 disease.¹⁰

There are meaningful differences by disease subtype, though. One study found that atypical p-ANCA was detected more frequently in PSC patients who also had IBD compared with those who did not, and that it was significantly more common in type 1 and type 3 AIH than in type 2 AIH.¹¹ If your doctor has ordered an atypical p-ANCA test alongside liver-function studies, these associations are likely part of the reasoning.

The Gut Microbiome Connection

One of the more intriguing lines of research into why atypical p-ANCA develops involves molecular mimicry between human proteins and bacterial proteins found in the gut. Atypical p-ANCA antibodies have been shown to recognize a human protein called β-tubulin isotype 5 along with a structurally similar bacterial protein called FtsZ. In animal models of IBD, this dual reactivity depends on an intact intestinal microbiome: germ-free animals (those raised without any gut bacteria) do not develop the response. The finding supports the idea that bacterial antigens can escape the gut, encounter the immune system, and trigger antibody production that cross-reacts with the body’s own cells.¹⁰ This “leaky gut” concept may also explain why atypical p-ANCA appears in both bowel and liver diseases that share an inflammatory gut component.

Less Common Associations

While IBD and autoimmune liver disease account for most positive atypical p-ANCA results, the antibody occasionally turns up elsewhere. In lupus spectrum disease, both classic ANCA and atypical p-ANCA have been observed as secondary autoantibodies. A published case described a patient with sight-threatening posterior scleritis whose atypical p-ANCA positivity turned out to be an early manifestation of lupus-spectrum illness rather than a primary vasculitis.¹²

Certain medications can also trigger ANCA positivity. Propylthiouracil, a drug used to treat hyperthyroidism, is one of the better-documented culprits. In one reported case, a critically ill patient developed both low blood counts and skin-related blood vessel inflammation while taking the drug. The diagnosis only became clear after a dermatologic and rheumatologic workup revealed ANCA positivity and vasculopathy on biopsy.¹³ If you have a positive ANCA result and are taking propylthiouracil, hydralazine, minocycline, or certain other medications, your doctor should consider drug-induced ANCA as a possibility.

Infective endocarditis, an infection of the heart valves, is another setting where ANCA can appear and muddy the waters. A systematic review found that ANCA positivity shows up in roughly 18–43% of patients with infective endocarditis, often mimicking vasculitis and leading to diagnostic confusion. The reassuring finding is that about 70% of those patients became ANCA-negative during follow-up after the infection was treated, and none went on to be diagnosed with a true systemic vasculitis.¹⁴

Why the Test Sometimes Gives Misleading Results

One of the most important technical pitfalls in atypical p-ANCA testing involves antinuclear antibodies, or ANA. Because the standard immunofluorescence test uses ethanol-fixed neutrophils, the cell membranes are disrupted, which allows positively charged proteins to drift toward the negatively charged DNA in the nucleus. This is the same process that creates the perinuclear staining pattern for classic anti-MPO antibodies, but it also means that ANA, which target nuclear antigens by definition, can mimic a p-ANCA pattern on the same test.¹⁵

The interference is not trivial. In one study, about 19% of samples that were positive for certain extractable nuclear antigens also showed a p-ANCA pattern on the ethanol-fixed slide, compared with only about 7% of those that were negative. The homogeneous ANA pattern, often linked to anti-double-stranded DNA antibodies, was the worst offender, producing apparent p-ANCA positivity in nearly a third of cases.¹⁶ This is why labs will often run ANA testing in parallel. If your ANA is positive, especially with a homogeneous pattern, a reported p-ANCA result needs to be interpreted with extra caution because the signal may be coming from the ANA rather than a true ANCA antibody.

How Immunofluorescence and Immunoassay Testing Compare

Immunofluorescence (the microscope-based method) remains the traditional first step in ANCA testing because it can detect the atypical patterns that automated blood tests miss. However, it is subjective: it requires a trained person to look at a slide and categorize the glow, which introduces variability between labs. Enzyme-linked immunoassays (ELISA), which directly measure antibodies against specific protein targets like MPO and PR3, are more standardized but were designed to catch the classic vasculitis-associated antibodies. They are not well suited to detecting atypical p-ANCA.

Studies comparing the two methods consistently find that ELISA misses a portion of cases that immunofluorescence catches, especially atypical patterns. One comparison reported that immunofluorescence detected ANCA in about 18% of tested samples while ELISA detected it in about 12%, and this gap was most pronounced for atypical patterns.¹⁷ A separate study confirmed this observation, finding that some immunofluorescence-positive samples came back negative on ELISA, and this discrepancy “occurred in all immunofluorescence patterns, but particularly in atypical patterns.”¹⁸

For patients and clinicians, this matters in a practical way. If your doctor suspects an IBD- or liver-related autoimmune process and orders only an ELISA-based ANCA panel, a negative result does not rule out atypical p-ANCA. The immunofluorescence test is the one capable of picking it up. Conversely, if you are being evaluated for classic vasculitis, modern guidelines increasingly favor starting with ELISA for anti-MPO and anti-PR3 antibodies, since the immunofluorescence test for those classic targets has a pooled sensitivity of only about 46% for p-ANCA patterns and carries a higher risk of false positives from ANA interference.¹⁹

Does a Positive Result Predict Future Disease Behavior?

One question patients reasonably ask is whether atypical p-ANCA levels can predict flares, complications, or the need for surgery. The evidence here is thin and mostly discouraging. In ulcerative colitis patients who have already had their colon removed, atypical p-ANCA often stays positive regardless of how well the person is doing. A study of patients who had undergone colectomy found that nearly all of those with a surgically created internal pouch tested positive for atypical p-ANCA, whether or not they had pouchitis (inflammation of the pouch). Even a patient who had opted for a permanent external pouch (Brooke’s ileostomy) tested positive. The researchers concluded that while atypical p-ANCA may mark persistent inflammation, a positive result should not be used to predict outcomes or guide decisions about pouch surgery.²⁰

This is a pattern that holds more broadly. Atypical p-ANCA is useful for categorizing disease and distinguishing between diagnostic possibilities, but there is no strong evidence supporting its use as a tool for monitoring disease activity over time or for making treatment decisions based on rising or falling levels. Your doctor is more likely to rely on symptoms, imaging, endoscopy, and inflammatory markers like C-reactive protein for those purposes.

When Atypical p-ANCA Shows Up Without Obvious Disease

Occasionally a person will have a positive atypical p-ANCA result without any clear symptoms of IBD, liver disease, or vasculitis. This happens more often than you might expect, especially when the test was ordered as part of a broad autoimmune panel rather than in response to a specific clinical suspicion. In these situations, the result needs to be interpreted in the full clinical context. A positive atypical p-ANCA in someone with no gastrointestinal symptoms, normal liver enzymes, and no signs of vasculitis is not, on its own, a reason to start treatment or undergo invasive testing.

That said, it is not something to ignore entirely. Some autoimmune conditions develop gradually, and a positive antibody result can precede the onset of symptoms by months or years. A reasonable approach, which most gastroenterologists and rheumatologists take, is to note the result, monitor for relevant symptoms over time, and repeat testing only if new clinical findings emerge. The key point is that the antibody is a marker of immune dysregulation, not a disease in itself. Treating a lab number rather than a patient leads to more harm than benefit.

How This Test Fits into the Broader ANCA Family

If you have been handed a lab report with ANCA results, it helps to know where atypical p-ANCA sits relative to the other patterns. Classic c-ANCA with anti-PR3 positivity is the pattern most closely tied to granulomatosis with polyangiitis (formerly Wegener’s), while classic p-ANCA with anti-MPO positivity is linked to microscopic polyangiitis and eosinophilic granulomatosis with polyangiitis.¹² These are serious systemic vasculitides that damage kidneys, lungs, and other organs. Atypical p-ANCA, with its different target proteins and different fluorescence pattern, points away from those conditions and toward the IBD and hepatobiliary spectrum. This distinction can be genuinely reassuring if you feared the result meant you had one of the more aggressive vasculitides.

The occasional overlap still exists. Lupus, drug reactions, and infections can all produce ANCA patterns that blur the lines between categories. And because no single lab test is 100% sensitive or specific, experienced clinicians always integrate the ANCA result with the entire clinical picture, including symptoms, organ involvement, biopsy findings, and complementary blood work. A positive atypical p-ANCA is a clue, sometimes an important one, but it is never the whole answer by itself.